Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our corporate responsibility activities.

A side effect is any unwanted medical occurrence in a patient who has been given a pharmaceutical product that may or may not have been caused by treatment with the product. By reporting side effects ...

Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review ...

Learn what cell and gene therapy is, how it differs from conventional medicine, and why it's creating a new turning point in how we treat disease.

We are an innovative medicines company with research and development at our core. Our R&D engine powers an industry-leading pipeline focused on delivering transformative medicines to fight disease, ...

Sickle Cell Disease (SCD) is an inherited blood disorder that affects almost eight million 1 people worldwide, causing tremendous suffering. It’s a life-threatening condition with chronic ...

The Novartis Institutes for BioMedical Research (NIBR) give students the opportunity to gain real-world disease research experience at a global biotech company.

Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU ...

Η Novartis συνεργάζεται με την κοινότητα των ασθενών σε όλο τον κόσμο για να ανακαλύψει νέους τρόπους βελτίωσης και παράτασης της ζωής των ανθρώπων.

Under the leadership of Vasant Narasimhan, the Executive Committee of Novartis (ECN) is responsible for overseeing the company's business operations.

Browse through the wide range of Novartis multimedia resources at your disposal.